Identity
- Security key
- 16073
- Ticker
- GLSI
- Type
- CS — Common Stock
- Exchange
- Nasdaq(XNAS)
- Venue group
- NASDAQ
- Operating MIC
- XNAS
- Market
- stocks
- Locale
- us
- Currency
- USD
- Listed
- 2020-09-25
- Round lot
- 100
- Active
- Yes
- Last seen in a load
- 2026-08-14 20:49
- Vendor updated
- 2026-08-13 06:09
- Ticker root / suffix
- GLSI
Detail
Enriched 2026-08-14 20:47
- Market cap
- $248,355,279.36
- Shares outstanding (class)
- 14,678,208
- Shares outstanding (weighted)
- 14,678,208
- SIC
- 2834 PHARMACEUTICAL PREPARATIONS
- Employees
- 13
- Location
- STAFFORD, TX
- Description
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9-amino-acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including breast cancers at low (1+), intermediate (2+), and high (3+ or overexpressing) levels.